SIMC yields 2000000.00% · PFE yields 6.20%● Live data
📍 SIMC pulled ahead of the other in Year 1
Combined, SIMC + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SIMC + PFE for your $10,000?
Simclar, Inc., together with its subsidiaries, operates as a contract manufacturer of electronic and electro-mechanical products in the United States and Mexico. Its custom-designed products include complex printed circuit boards (PCBs), finished products, subassemblies, molded and nonmolded cable assemblies, wire harnesses, injection molded, and electronic assembly products. The PCBs produced by the company comprise pin-through-hole assemblies, low and medium volume surface mount technology assemblies, and mixed technology PCBs, including multilayer PCBs; and cable and harness assemblies consist of multiconductor, ribbon, coaxial cable, and discrete wire harness assemblies. The company also provides contract manufacturing services, which involves the manufacture of complete finished assemblies with all sheet metal, power supplies, fans, and PCBs, as well as complete sub-assemblies for integration into original equipment manufactures (OEMs) finished products, such as speaker and lock-key assemblies, and diode assemblies. In addition, Simclar offers reworking and refurbishing services, which comprise redesign, rework, refurbish, and repair of materials and subassemblies; sheet metal fabrication services; and backplane interconnect solutions. The company's products are manufactured to customer specifications and designed for OEMs in the data processing, telecommunications, instrumentation, and food preparation equipment industries. The company was formerly known as Techdyne, Inc. and changed its name to Simclar, Inc. in September 2003. The company was founded in 1976 and is based in Hialeah, Florida. Simclar, Inc. operates as a subsidiary of Simclar Group Limited.
Full SIMC Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.